ATE198276T1 - Verwendung von lanthanide-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzen in einem hautpflegemittel - Google Patents

Verwendung von lanthanide-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzen in einem hautpflegemittel

Info

Publication number: ATE198276T1
Authority: AT; Austria
Prior art keywords: yttrium; barium; cobalt; tin; manganeous
Prior art date: 1995-10-26

Application number

AT96402180T

Other languages

English (en)

Inventor

Lacharriere Olivier De

Lionel Breton

Original Assignee

Oreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-14

Publication date

2001-01-15

1996-10-14 Application filed by Oreal filed Critical Oreal

2001-01-15 Application granted granted Critical

2001-01-15 Publication of ATE198276T1 publication Critical patent/ATE198276T1/de

Links

ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 title abstract 2
229910052788 barium Inorganic materials 0.000 title abstract 2
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 title abstract 2
229910017052 cobalt Inorganic materials 0.000 title abstract 2
239000010941 cobalt Substances 0.000 title abstract 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 title abstract 2
229910052727 yttrium Inorganic materials 0.000 title abstract 2
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 title abstract 2
229910052747 lanthanoid Inorganic materials 0.000 title 1
150000002602 lanthanoids Chemical class 0.000 title 1
159000000008 strontium salts Chemical class 0.000 title 1
208000007514 Herpes zoster Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
229910052684 Cerium Inorganic materials 0.000 abstract 1
229910052692 Dysprosium Inorganic materials 0.000 abstract 1
229910052691 Erbium Inorganic materials 0.000 abstract 1
229910052693 Europium Inorganic materials 0.000 abstract 1
206010016654 Fibrosis Diseases 0.000 abstract 1
229910052688 Gadolinium Inorganic materials 0.000 abstract 1
229910052689 Holmium Inorganic materials 0.000 abstract 1
229910052765 Lutetium Inorganic materials 0.000 abstract 1
229910052779 Neodymium Inorganic materials 0.000 abstract 1
229910052777 Praseodymium Inorganic materials 0.000 abstract 1
229910052773 Promethium Inorganic materials 0.000 abstract 1
229910052772 Samarium Inorganic materials 0.000 abstract 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
229910052771 Terbium Inorganic materials 0.000 abstract 1
229910052775 Thulium Inorganic materials 0.000 abstract 1
208000025865 Ulcer Diseases 0.000 abstract 1
229910052769 Ytterbium Inorganic materials 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical class [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract 1
239000002537 cosmetic Substances 0.000 abstract 1
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical class [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 abstract 1
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical class [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 abstract 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical class [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 abstract 1
230000004761 fibrosis Effects 0.000 abstract 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical class [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract 1
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical class [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 abstract 1
230000001969 hypertrophic effect Effects 0.000 abstract 1
229910052746 lanthanum Inorganic materials 0.000 abstract 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical class [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract 1
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 abstract 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical class [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 abstract 1
PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical class [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 abstract 1
VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical class [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 abstract 1
201000004700 rosacea Diseases 0.000 abstract 1
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical class [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 abstract 1
208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1
229910052712 strontium Inorganic materials 0.000 abstract 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 abstract 1
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical class [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 abstract 1
229910052718 tin Inorganic materials 0.000 abstract 1
239000011135 tin Substances 0.000 abstract 1
231100000397 ulcer Toxicity 0.000 abstract 1
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

AT96402180T 1995-10-26 1996-10-14 Verwendung von lanthanide-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzen in einem hautpflegemittel ATE198276T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9512656A FR2740341B1 (fr)	1995-10-26	1995-10-26	Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau

Publications (1)

Publication Number	Publication Date
ATE198276T1 true ATE198276T1 (de)	2001-01-15

Family

ID=9483957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96402180T ATE198276T1 (de)	1995-10-26	1996-10-14	Verwendung von lanthanide-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzen in einem hautpflegemittel

Country Status (9)

Country	Link
US (1)	US5866168A (de)
EP (1)	EP0775492B1 (de)
JP (1)	JPH09169657A (de)
AT (1)	ATE198276T1 (de)
CA (1)	CA2188688C (de)
DE (1)	DE69611343T2 (de)
ES (1)	ES2155179T3 (de)
FR (1)	FR2740341B1 (de)
NO (1)	NO319503B1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6203803B1 (en)	1994-12-14	2001-03-20	Societe L'oreal S.A.	Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US7404967B2 (en) *	1994-12-21	2008-07-29	Cosmederm, Inc.	Topical product formulations containing strontium for reducing skin irritation
US6139850A (en) *	1994-12-21	2000-10-31	Cosmederm Technologies	Formulations and methods for reducing skin irritation
FR2740340B1 (fr) *	1995-10-30	1997-12-05	Oreal	Utilisation d'acides carboxyliques porteurs d'une fonction soufree pour favoriser la desquamation de la peau ou stimuler le renouvellement epidermique
US7069087B2 (en)	2000-02-25	2006-06-27	Oratec Interventions, Inc.	Apparatus and method for accessing and performing a function within an intervertebral disc
US6126682A (en)	1996-08-13	2000-10-03	Oratec Interventions, Inc.	Method for treating annular fissures in intervertebral discs
US6168798B1 (en) *	1997-02-03	2001-01-02	Bristol-Myers Squibb Company	Non-irritating composition for treating acne and other skin conditions
US6248370B1 (en) *	1997-07-24	2001-06-19	Leroy Harris	Skin treatment and methods
AT405017B (de) *	1997-10-06	1999-04-26	Jakoby Marie Luise	Mittel zur stimulation der körpereigenen abwehr
FR2774285B1 (fr) *	1998-02-03	2001-06-15	Roche Posay Lab Pharma	Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
ATE239490T1 (de) *	1999-07-09	2003-05-15	Bsp Pharma As	Zusammensetzung enthaltend butyrospermum parkii extrakte und die verwendung als arzneimittel oder nahrungszusatz
DE10043466A1 (de) *	2000-09-04	2002-03-28	Johannes Wohlrab	Manganverbindungen enthaltende Zubereitung zur topischen Applikation und deren Verwendungen
ES2181586B1 (es) *	2001-05-03	2004-06-16	Alfonso Blanco Cobo	Producto farmaceutico para el tratamiento de tumores cancerigenos.
NO20014746D0 (no) *	2001-09-28	2001-09-28	Clas M Kjoelberg	Smertelindrende middel
US7879365B2 (en) *	2002-02-07	2011-02-01	The Trustees Of Columbia University In The City Of New York	Zinc salt compositions for the prevention of dermal and mucosal irritation
EP1499325B1 (de) *	2002-04-30	2008-07-16	Hisamitsu Pharmaceutical Co., Inc.	Zusammesetzung enthaltend trehalose und zink und deren verwendung zur hemmung der hautreizung
US7081247B2 (en) *	2002-05-20	2006-07-25	Nidaria Technology Ltd.	Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
FR2846558B1 (fr) *	2002-11-05	2006-07-14	Servier Lab	Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
WO2004052326A1 (en) *	2002-12-09	2004-06-24	Evgeny Nikolaevich Ananiev	Pharmaceutical or cosmetic composition, preventing or reducing itch and local reaction from stings of insects
CA2561082C (en) *	2003-03-27	2014-07-15	Santosolve As	Anti-inflammatory treatment based on strontium compounds
EP1622630B1 (de) *	2003-05-07	2012-08-29	Osteologix A/S	Strontium-kombinationsbehandlung zur prophylaxe/behandlung von knorpel- und knochenzuständen
ES2275218T3 (es) *	2003-05-07	2007-06-01	Osteologix A/S	Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
BRPI0412675A (pt) *	2003-07-17	2006-10-03	Univ Columbia	composições antimicrobianas contendo combinações sinergìsticas de compostos de amÈnio quaternário e óleos essenciais e/ou constituintes
ES2342461T3 (es) *	2003-10-17	2010-07-07	Oy Neurofood Ab	Agente de estroncio no radiactivo para tratar el cancer.
WO2005053613A2 (en) *	2003-11-26	2005-06-16	Combinatorx, Inc.	Combinations for the treatment of fungal infections
US7258875B2 (en) *	2003-12-04	2007-08-21	Chiou Consulting, Inc.	Compositions and methods for topical treatment of skin infection
FR2866810B1 (fr) *	2004-03-01	2006-04-28	Oreal	Utilisation d'au moins un inhibiteur des canaux calciques pour prevenir et/ou traiter la peau grasse.
GB0517043D0 (en) *	2005-08-19	2005-09-28	York Pharma Plc	Improvements in pharmaceutical compositions
WO2007062060A2 (en)	2005-11-22	2007-05-31	Ted Reid	Methods and compositions using substance p to promote wound healing
EP2066289A4 (de) *	2006-08-25	2013-11-27	Micellbio Co Ltd	Verwendungen von selten erdelementen für die haarverbesserung
KR100769260B1 (ko) *	2006-08-25	2007-10-22	주식회사 태웅이엘에스	희토원소를 함유하는 모발 개선용 조성물
GB0617191D0 (en) *	2006-08-31	2006-10-11	York Pharma Plc	Improvements in pharmaceutical compositions
KR101729096B1 (ko)	2012-03-21	2017-04-21	코스메덤 바이오사이언스, 인코퍼레이티드	통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체
WO2016141219A1 (en) *	2015-03-05	2016-09-09	Cosmederm Bioscience, Inc.	Strontium based compositions and formulations for pain, pruritus, and inflammation
US11235002B2 (en)	2015-08-21	2022-02-01	Galleon Labs Llc	Strontium based compositions and formulations for pain, pruritus, and inflammation
US12139415B2 (en)	2018-10-31	2024-11-12	Yeditepe Üniversitesi	Use of nano-sized lanthanide borate (dysprosium borate and erbium borate) compounds for wound healing purposes and production method thereof
US20220257646A1 (en) *	2019-07-18	2022-08-18	The Regents Of The University Of California	Compositions and methods for treating skin conditions
TR202021285A1 (tr) *	2020-12-22	2022-07-21	Univ Yeditepe	Yara skarinin önlenmesi̇ ve tedavi̇si̇nde kullanilmak üzere erbium borat i̇çeren formülasyon
AU2022459560A1 (en) *	2022-06-13	2024-01-04	Sevda Demir	Use of lutetium salt compounds for antiviral effect

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE297062C (de) *
GB997975A (en) *	1964-01-31	1965-07-14	Aristotelis Papageorgiou Lambo	Pharmaceutical compositions containing a cresol or a mixture of cresols
GB1072355A (en) *	1964-06-17	1967-06-14	Michael Collin	Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) *	1967-09-01	1970-07-07	Robert E Svigals	Composition and method of treating pruritic conditions of the skin
IE35991B1 (en) *	1971-01-22	1976-07-21	Comprehensive Pharmaceuticals	Improvements in or relating to the treatment of diseases of the skin and mucosa
LU65373A1 (de) *	1972-05-17	1973-11-23
US3772431A (en) *	1972-09-21	1973-11-13	W Mlkvy	Effervescent mouthwash tablet
US3888976A (en) *	1972-09-21	1975-06-10	William P Mlkvy	Zinc and strontium ion containing effervescent mouthwash tablet
US4477439A (en) *	1981-04-13	1984-10-16	Walter J. Monacelli	Treatment of irritated and excoriated areas around the stoma of ostomy patients
EP0090798A1 (de) *	1981-10-09	1983-10-12	Ferring AB	Arzneimittel auf der basis eines antagonisten der p-substanz
AU556817B2 (en) *	1982-02-03	1986-11-20	Efamol Limited	Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8320203D0 (en) *	1983-07-27	1983-09-01	Horrobin D F	Anti-viral compositions
DE3338957A1 (de) *	1983-10-27	1985-05-15	Keyhan Dipl.-Ing. 6908 Wiesloch Ghawami	Enthaarungsmittel
US4711780A (en) *	1984-06-11	1987-12-08	Fahim Mostafa S	Composition and process for promoting epithelial regeneration
IT1214611B (it) *	1985-05-22	1990-01-18	Schiena Ricerche	Composti per uso cosmetico dermatologico e relative composizioni.
US4837026A (en) *	1985-10-03	1989-06-06	Rajakhyaksha Vithal J	Transdermal and systemic preparation and method
ATE69954T1 (de) *	1985-10-08	1991-12-15	Psori Med Ag	Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
US4735802A (en) *	1986-05-05	1988-04-05	Le Bich N	Topical dermatological composition and method of treatment
FR2599967B1 (fr) *	1986-06-16	1989-03-31	Bfb Etudes Rech Experimentale	Utilisation de sel de zinc et de la vitamine b6 pour enrayer les processus alopeciques et/ou seborrheiques.
US4986981A (en) *	1986-07-07	1991-01-22	Den Mat Corporation	Toothpaste having low abrasion
US5091171B2 (en) *	1986-12-23	1997-07-15	Tristrata Inc	Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) *	1987-04-02	1988-10-03	Boliden Ab	Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) *	1988-09-22	1990-03-29	Siegfried Natterer	Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
FR2644063B1 (fr) *	1989-03-13	1991-06-14	Fabre Pierre Cosmetique	Compositions dermatologiques et cosmetologiques a base d'alcoylcarboxamide et de sel de zinc utiles dans le traitement de la dermite seborrheique et/ou des troubles de la seborrhee
CA2014201A1 (en) *	1989-04-26	1990-10-26	Albemarle Corporation	Solid non-hygroscopic trialkylamine oxides
US5132119A (en) *	1989-07-31	1992-07-21	Massachusetts Institute Of Technology	Treatment of hypertrophic wound healing disorders with calcium channel blockers
JP3149180B2 (ja) *	1989-07-31	2001-03-26	マサチユセツツ・インスチチユート・オブ・テクノロジー	瘢痕治療のためのカルシウム拮抗薬の使用
IL95393A0 (en) *	1989-08-18	1991-06-30	John Morris Co	Odor-masked and stabilized compositions for treating keratinous tissue,skin conditions,and promoting wound healing
US5202130A (en) *	1989-08-31	1993-04-13	The Johns Hopkins University	Suppression of eczematous dermatitis by calcium transport inhibition
US5296476A (en) *	1989-09-08	1994-03-22	Henderson Esther G	Skin care compositions
EP0439640B1 (de) *	1990-01-29	1993-09-15	WOGEPHARM GmbH	Verfahren zur Herstellung von Mitteln zur Therapie von Hauterkrankungen
EP0451300B1 (de) *	1990-04-10	1994-10-26	Romuald Dr. Kowalski	Bariumsulfat-kolloidale Dispersion enthaltende Zusammensetzung
FR2662607B1 (fr) *	1990-05-30	1992-08-28	Oreal	Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
JPH06509332A (ja) *	1991-07-05	1994-10-20	メルク　シヤープ　エンド　ドーム　リミテツド	芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
WO1993001165A2 (en) *	1991-07-10	1993-01-21	Merck Sharp & Dohme Limited	Aromatic compounds, compositions containing them and their use in therapy
RU2038072C1 (ru) *	1991-11-01	1995-06-27	Государственный российский научно-исследовательский институт органической химии и технологии	Крем для защиты кожи от химических веществ и способ его получения
GB9201179D0 (en) *	1992-01-21	1992-03-11	Glaxo Group Ltd	Chemical compounds
DE4227203C2 (de) *	1992-08-17	1994-03-24	Kao Corp Gmbh	Mittel und Verfahren zur Haarbehandlung
GB9222486D0 (en) *	1992-10-26	1992-12-09	Merck Sharp & Dohme	Therapeutic agents
WO1994009798A1 (en) *	1992-10-29	1994-05-11	C-P Technology Limited Partnership	Mixtures or complexes containing calcium and sulfate
US5593992A (en) *	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
US6455076B1 (en) *	1994-12-21	2002-09-24	Gary S. Hahn	Formulations and methods for reducing skin irritation
US5716625A (en) *	1994-12-21	1998-02-10	Cosmederm Technologies	Formulations and methods for reducing skin irritation
EP0799018A4 (de) *	1994-12-21	2000-03-29	Cosmederm Technologies	Formulierungen und verfahren zur verminderung von hautirritationen
DE4446521A1 (de) *	1994-12-24	1996-06-27	Estee Lauder Inc	Mascara-Bürstchen

1995
- 1995-10-26 FR FR9512656A patent/FR2740341B1/fr not_active Expired - Fee Related
1996
- 1996-10-14 DE DE69611343T patent/DE69611343T2/de not_active Expired - Fee Related
- 1996-10-14 AT AT96402180T patent/ATE198276T1/de active
- 1996-10-14 EP EP96402180A patent/EP0775492B1/de not_active Expired - Lifetime
- 1996-10-14 ES ES96402180T patent/ES2155179T3/es not_active Expired - Lifetime
- 1996-10-23 CA CA002188688A patent/CA2188688C/fr not_active Expired - Fee Related
- 1996-10-24 NO NO19964515A patent/NO319503B1/no unknown
- 1996-10-25 JP JP8284316A patent/JPH09169657A/ja active Pending
- 1996-10-28 US US08/740,311 patent/US5866168A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0775492B1 (de)	2000-12-27
DE69611343D1 (de)	2001-02-01
NO319503B1 (no)	2005-08-22
DE69611343T2 (de)	2001-04-26
ES2155179T3 (es)	2001-05-01
NO964515L (no)	1997-04-28
JPH09169657A (ja)	1997-06-30
CA2188688C (fr)	2002-12-17
EP0775492A1 (de)	1997-05-28
FR2740341B1 (fr)	1997-12-19
US5866168A (en)	1999-02-02
NO964515D0 (no)	1996-10-24
CA2188688A1 (fr)	1997-04-27
FR2740341A1 (fr)	1997-04-30

Publication	Publication Date	Title
ATE198276T1 (de)	2001-01-15	Verwendung von lanthanide-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzen in einem hautpflegemittel
EP0770392A3 (de)	1997-05-07	Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einer pharmazeutische Zusammensetzung
WO1991014437A3 (en)	1991-11-28	Use of copper(ii) containing compounds to accelerate wound healing
WO2002036534A3 (en)	2004-02-19	Processes for preparing linear polyglycerols and polyglycerol esters
DE59305359D1 (de)	1997-03-13	Desodorierende kosmetische zubereitungen mit einem gehalt an di- oder triglycerinestern
DE3687099D1 (de)	1992-12-17	Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
CA2377544A1 (en)	2001-02-01	Hyaluronic acid anti-adhesion barrier
IS4328A (is)	1996-03-04	Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
GR3021424T3 (en)	1997-01-31	Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity
IL107370A0 (en)	1994-01-25	Stabilized aqueous solutions containing sorbic acid or salt thereof
DE60016460D1 (de)	2005-01-05	Verwendungen und zusammenstellungen von nitratestern als sedativa
CA2108707A1 (en)	1994-04-21	Esters of l-carnitine and alkanoyl l-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses
IL110808A (en)	2003-03-12	Pharmaceutical compositions containing aromatic and araliphatic carboxylic acid derivatives for treating light and age-damaged skin and for promoting wound healing and some novel such compounds
EP0934748A3 (de)	2001-01-31	Von Willenbrand Faktor (vWF) enthaltende Zubereitung, verfahren zür Herstellung von vWF enthaltenden Zubereitungen und deren Verwendung
GR1002610B (el)	1997-02-20	Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
CA2059558A1 (en)	1991-02-01	Use of calcium antagonists for treating scars
WO2002028420A3 (en)	2003-08-14	Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
EP0770391A3 (de)	1997-05-07	Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in pharmazeutische Zubereitungen
DE69312605D1 (de)	1997-09-04	Neutronenaktivierbare Kationen enthaltende lipophile Zusammensetzungen
AU5270693A (en)	1994-07-07	Pharmaceutical composition for preventing or treating arteriosclerosis
DE59911108D1 (de)	2004-12-23	Oligomere und hochmolekulare umsetzungsprodukte von allophansäureestern mit nucleophilen verbindungen sowie ihre verwendung
FI952805L (fi)	1995-06-07	Asetosalisyylihappoa sisältävä transdermaalinen vapautumisjärjestelmä antitromboottiseen terapiaan ja syövän ennaltaehkäisyyn
GB9900325D0 (en)	1999-02-24	Topical pharmaceutical compositions for healing wounds
DE69502854D1 (de)	1998-07-16	Zusammensetzung zur Bekämpfung von Hautflecken und/oder Hautalterung und ihre Verwendungen
AU5729194A (en)	1994-06-22	Compositions for treating corns, calluses and warts comprising salicylic acid and lanthanide